Cargando…
Antidepressants for COVID-19: A systematic review
OBJECTIVE: To systematically examine the efficacy and safety of antidepressants for the treatment of coronavirus disease 2019 (COVID-19). METHODS: A systematic search was performed independently by two researchers based on Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941844/ https://www.ncbi.nlm.nih.gov/pubmed/35339571 http://dx.doi.org/10.1016/j.jad.2022.03.059 |
_version_ | 1784673187746807808 |
---|---|
author | Zheng, Wei Sun, He-Li Cai, Hong Zhang, Qinge Ng, Chee H. Xiang, Yu-Tao |
author_facet | Zheng, Wei Sun, He-Li Cai, Hong Zhang, Qinge Ng, Chee H. Xiang, Yu-Tao |
author_sort | Zheng, Wei |
collection | PubMed |
description | OBJECTIVE: To systematically examine the efficacy and safety of antidepressants for the treatment of coronavirus disease 2019 (COVID-19). METHODS: A systematic search was performed independently by two researchers based on Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE. RESULTS: Seven studies (n = 92,947) including three retrospective studies (n = 91,083), two randomized clinical trials (RCTs, n = 1649), two prospective cohort study (n = 215) involving (n = 92,947) patients with COVID-19 were examined. For RCTs, fluvoxamine outperformed placebo in reducing clinical deterioration and hospitalisation for COVID-19 patients. For retrospective studies, antidepressants (2 studies) and fluoxetine (1 study) possibly reduced the risk of mortality in patients with COVID-19. Results from two remaining studies supported the superiority of fluvoxamine in reducing risk of mortality in COVID-19 patients. The two RCTs that examined the safety of fluvoxamine for COVID-19 patients found inconsistent results but no significant group differences in the dropout rate. CONCLUSION: This systematic review found emerging evidence for fluvoxamine in reducing the risk of mortality and hospitalisation in COVID-19 patients, but inconsistent evidence for the safety of fluvoxamine in COVID-19 patients. More studies are needed to determine the efficacy and safety of antidepressants for the treatment of COVID-19. |
format | Online Article Text |
id | pubmed-8941844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89418442022-03-24 Antidepressants for COVID-19: A systematic review Zheng, Wei Sun, He-Li Cai, Hong Zhang, Qinge Ng, Chee H. Xiang, Yu-Tao J Affect Disord Review Article OBJECTIVE: To systematically examine the efficacy and safety of antidepressants for the treatment of coronavirus disease 2019 (COVID-19). METHODS: A systematic search was performed independently by two researchers based on Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE. RESULTS: Seven studies (n = 92,947) including three retrospective studies (n = 91,083), two randomized clinical trials (RCTs, n = 1649), two prospective cohort study (n = 215) involving (n = 92,947) patients with COVID-19 were examined. For RCTs, fluvoxamine outperformed placebo in reducing clinical deterioration and hospitalisation for COVID-19 patients. For retrospective studies, antidepressants (2 studies) and fluoxetine (1 study) possibly reduced the risk of mortality in patients with COVID-19. Results from two remaining studies supported the superiority of fluvoxamine in reducing risk of mortality in COVID-19 patients. The two RCTs that examined the safety of fluvoxamine for COVID-19 patients found inconsistent results but no significant group differences in the dropout rate. CONCLUSION: This systematic review found emerging evidence for fluvoxamine in reducing the risk of mortality and hospitalisation in COVID-19 patients, but inconsistent evidence for the safety of fluvoxamine in COVID-19 patients. More studies are needed to determine the efficacy and safety of antidepressants for the treatment of COVID-19. Elsevier B.V. 2022-06-15 2022-03-23 /pmc/articles/PMC8941844/ /pubmed/35339571 http://dx.doi.org/10.1016/j.jad.2022.03.059 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Zheng, Wei Sun, He-Li Cai, Hong Zhang, Qinge Ng, Chee H. Xiang, Yu-Tao Antidepressants for COVID-19: A systematic review |
title | Antidepressants for COVID-19: A systematic review |
title_full | Antidepressants for COVID-19: A systematic review |
title_fullStr | Antidepressants for COVID-19: A systematic review |
title_full_unstemmed | Antidepressants for COVID-19: A systematic review |
title_short | Antidepressants for COVID-19: A systematic review |
title_sort | antidepressants for covid-19: a systematic review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941844/ https://www.ncbi.nlm.nih.gov/pubmed/35339571 http://dx.doi.org/10.1016/j.jad.2022.03.059 |
work_keys_str_mv | AT zhengwei antidepressantsforcovid19asystematicreview AT sunheli antidepressantsforcovid19asystematicreview AT caihong antidepressantsforcovid19asystematicreview AT zhangqinge antidepressantsforcovid19asystematicreview AT ngcheeh antidepressantsforcovid19asystematicreview AT xiangyutao antidepressantsforcovid19asystematicreview |